← Back to Screener
Immix Biopharma, Inc. Common Stock (IMMX)
Price$10.09
Favorite Metrics
Price vs S&P 500 (26W)305.25%
Price vs S&P 500 (4W)4.12%
Market Capitalization$548.68M
All Metrics
Book Value / Share (Quarterly)$1.77
P/TBV (Annual)7.20x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.47
Price vs S&P 500 (YTD)93.76%
EPS (TTM)$-0.88
10-Day Avg Trading Volume0.68M
EPS Excl Extra (TTM)$-0.88
EPS (Annual)$-0.89
ROI (Annual)-31.39%
Cash / Share (Quarterly)$1.90
ROA (Last FY)-28.08%
EBITD / Share (TTM)$-0.90
ROE (5Y Avg)-97.32%
Cash Flow / Share (Annual)$-0.47
P/B Ratio5.85x
P/B Ratio (Quarterly)2.94x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-0.06x
ROA (TTM)-73.39%
EPS Incl Extra (Annual)$-0.89
Current Ratio (Annual)10.01x
Quick Ratio (Quarterly)9.95x
3-Month Avg Trading Volume1.00M
52-Week Price Return559.24%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.01
52-Week High$11.61
EPS Excl Extra (Annual)$-0.89
CapEx CAGR (5Y)159.54%
26-Week Price Return314.00%
Quick Ratio (Annual)9.95x
13-Week Price Return108.67%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.01x
Enterprise Value$454.747
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.90
3-Month Return Std Dev84.34%
Net Income / Employee (TTM)$-2
ROE (Last FY)-31.39%
Net Interest Coverage (Annual)-0.05x
EPS Basic Excl Extra (Annual)$-0.89
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.88
ROI (TTM)-101.24%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.95
Price vs S&P 500 (52W)524.14%
Year-to-Date Return97.90%
5-Day Price Return6.81%
EPS Normalized (Annual)$-0.89
ROA (5Y Avg)-77.78%
Month-to-Date Return13.61%
Cash Flow / Share (TTM)$-0.93
EBITD / Share (Annual)$-0.90
ROI (5Y Avg)-97.24%
EPS Basic Excl Extra (TTM)$-0.88
P/TBV (Quarterly)4.79x
P/B Ratio (Annual)2.94x
Book Value / Share (Annual)$1.77
Price vs S&P 500 (13W)105.80%
Beta0.23x
Revenue / Share (TTM)$0.00
ROE (TTM)-101.24%
52-Week Low$1.57
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.13
4.10
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IMMXImmix Biopharma, Inc. Common Stock | — | — | — | — | $10.09 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Immix Biopharma is a clinical-stage biopharmaceutical company developing novel cell therapies for oncology and inflammatory diseases using its proprietary TME Normalization Technology. This platform enables therapeutics to penetrate tumors and simultaneously target multiple components of the tumor microenvironment. The company's pipeline includes CAR-T candidate NXC-201 for autoimmune diseases and IMX-110 for soft tissue sarcoma.